RD-R191 439	CONDINATION ANTIVIRAL D COLVESTON D	CHENOTHERAPHY RUGS AGA. (U) T	USING IMMUN EXAS UNIV M	E MODULATOR EDICAL BRAN	S AND Ch At	1/1
UNCLASSIFIED	30 NAR 87 D	AND17-86-C-6119		F/G	6/15	<u>NL</u>
				2 - B		
, <u>-</u>						
<u> </u>						



AD-A191 439

ĸĬŎĔĸĊŔĔĸŢŎĔĸĊŔĔĸĬŔĔĸĬŔĔĸĔŔĔĸĬŔĔĸĔĸĔ

# DTIC FILE CUPY

AD

Combination Chemotherapy Using Immune Modulators and Antiviral Drugs Against Togaviruses and Bunyaviruses

Subtitle: Prescreening and Test Systems

ANNUAL REPORT

D.H. Coppenhaver, M. Sarzotti, I.P. Singh, H. Lucia and S. Baron

March 30, 1987

Supported by

<sup>•</sup> U.S. Army Medical Research and Development command Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-86-C-6119

University of Texas Medical Branch Galveston, TX 77550

DOD DISTRIBUTION STATEMENT:

Approved for public release; distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other author rized documents.

881 26 049



•			REPORT DOCU	MENTATION	PAGE		
1. REPORT	SECURITY CLASS	IFICATION		16. RESTRICTIVE	MARKINGS		
28. SECURITY	CLASSIFICATIO	N AUTHORITY		3. DISTRIBUTION/AVAILABILITY OF REPORT			
26. DECLASS	FICATION / DOV	UNGRADING SCHEDU		Approved i	for public	release;	
		ION REPORT NUMBE	P(S)		ORGANIZATION	EU	6/C)
4. r gar Grinn							
60. NAME OF Depart	PERFORMING	ORGANIZATION icrobiology	6b. OFFICE SYMBOL (If applicable)	7a. NAME OF MO	DNITORING ORG	ANIZATION	
6C ADDRESS	(City, State, and	d ZIP Code)	J	7b. ADDRESS (Cit	y, State, and ZIP	Code)	
Calves	stop TX 7	7550			-		
Garves	IA /						
Sa. NAME OF ORGANIZ Resear	FUNDING/SPO ATION U.S. Ich and De	NSORING Army Medical velopment Com	8b. OFFICE SYM8OL (If applicable) hand	9. PROCUREMENT DAMD17-	r instrument ic 86-C-6119	DENTIFICATION	NUMBER
SC ADDRESS	(City, State, and	I ZIP Code)	•	10 SOURCE OF F	UNDING NUMBE	RS	
Fort I	Detrick	1701-5012		PROGRAM ELEMENT NO.	PROJECT NO. 3M2	TASK NO.	WORK UNIT
rreael	LICK, MD Z			63763A	63763D807	AĎ	380
D.H. Cor 13a. TYPE OF Annua	Denhaver,	MSarzotti, 13b. Time co FROM_3/	I.P. Singh, H. DVERED 1/36 TO 2/28/87	Lucia, and 14. DATE OF REPO 1987, M	S. Baron Af (Year, Month, arch 30	Day) 15. PAG	SE COUNT
D.H. Cor 13a. TYPE OF Annua 16. SUPPLEM	L AUTHOR(S) <u>openhaver</u> , <b>REPORT</b> al ENTARY NOTAT	M. Sarzotti, 13b. Time Co FROM_3/	I.P. Singh, H. DVERED 1/36_ TO _2/28/87	Lucia, and 14. DATE OF REPO 1987, M	S. Baron RT (Yesr, Month, arch 30	Day) 15. PAC	SE COUNT
D.H. Cop 13a. TYPE OF Annua 16. SUPPLEM	COSATI	M. Sarzotti, 13b. TIME CO FROM_3/	I.P. Singh, H. DVERED 1/36_ TO 2/28/87	Lucia, and 14. DATE OF REPO 1987, M	S. Baron RT (Year, Month, arch 30	Day) 15. PAC	SE COUNT 38
D.H. Cor 13a. TYPE OF Annua 16. SUPPLEMI 17. FIELD 06	COSATI GROUP	M. Sarzotti, 13b. TIME CC FROM 3/ TION CODES SUB-GROUP	I.P. Singh, H. DVERED 1/36_ TO 2/28/87	Lucia, and 14. DATE OF REPO 1987, M Continue on reverse ators, antiv	S. Baron Rf (Year, Month, arch 30 I f necessary an irals, arbo	Day) 15. PAC d identify by b oviruses,	SE COUNT 38 Noch number) arenaviruses
D.H. Cor 13a. TYPE OF Annua 16. SUPPLEMI 17. FIELD 06 06 19. ABSTRACT - In:	COSATI GROUP 13 COSATI GROUP 13 COSATI GROUP 13 COSATI Continue on fections c	M. Sarzotti, 13b. TIME CO FROM 3/ TION CODES SUB-GROUP Foverse if necessary aused by exot	I.P. Singh, H. DVERED 1/36_TO_2/28/87 18. SUBJECT TERMS ( Immunonodul combination and identify by block ( ic viruses are	Lucia, and 14. DATE OF REPO 1987, M Continue on reverse ators, antiv therapy number) an important	S. Baron RT (Yes, Month, arch 30 If necessary on irals, arbo publich he	Day) 15. PAC d identify by b oviruses, a salth prob	38 Work number) arenaviruses lem world-
D.H. Cor Annua 13a. TYPE OF Annua 16. SUPPLEM 17. FIELD 06 06 06 19. ABSTRACT JIN: wide, an four mer antivir, (Banzi, were str of cand est. T weanlin form the viral d	COSATI COSATI	M. Sarzotti, 13b. TIME (C FROM_3/ TON CODES SUB-GROUP aused by exot hreat to becomportant group es. Select A b), Bunyavirus del systems w viral substant omising compo- dels, to estator or designing compo-	I.P. Singh, H. DVERED 1/36_TO_2/28/87 I. SUBJECT TERMS ( Immunonodul combination and dentify by block of ic viruses are me more widely s were chosen a lphaviruses (Se tes (Bunyamwera, pere established tes identified bunds were exami- ablish minimal to combination ther	Lucia, and 14. DATE OF REPO 1987, M Continue on reverse ators, antiv therapy number) an important desiminated. is model syst mliki Forest LaCrosse), in vitro an compounds of ined in vivo, herapeutic 1 capies using	S. Baron AT (Yes, Month, arch 30 M necessary and irals, arbo publich he Represent ems to inve , Sindbis); and an Aren d <u>in vivo</u> . potential using Seml evels. The immune modu	<b>Doy)</b> 15. PAC a identity by b oviruses, a ealth prob ative virus estigate po Flavivirus New York In vitro therapeut liki Fores ese experind lators and	SE COUNT 38 Moct number) arenaviruses lem world- uses from otential uses ichinde) screens ic inter- t and Banzi ments will d anti-
D.H. Cor 13a. TYPE OF Annua 16. SUPPLEM 17. FIELD 06 06 19. ABSTRAC PIN wide, and four med antivira (Banzi, were stu of cand est. The weanling form the viral d	COSATIO COS	M. Sarzotti, 13b. TIME CO FROM _3/ TON CODES SUB-GROUP reverse if necessary aused by exot hreat to beco portant group es. Select A b), Bunyavirus del systems w viral substant omising compo dels, to esta or designing compo dels, to esta	I.P. Singh, H. DVERED 1/36_TO_2/28/87 I.SUBJECT TERMS ( Immunonodul combination and identify by block i ic viruses are me more widely is were chosen a lphaviruses (Se ses (Bunyamwera, pere established ounds were exami- blish minimal to combination there	Lucia, and 14. DATE OF REPO 1987, M Continue on reverse ators, antiv therapy number) an important desiminated. is model syst mliki Forest LaCrosse), <u>in vitro</u> an compounds of ned <u>in vivo</u> , herapeutic 1 capies using	S. Baron RT (Yes, Month, arch 30 If necessary and irals, arbo publich he Represent ems to inve , Sindbis); and an Aren d <u>in vivo</u> . potential using Seml evels. The immune modu	<b>Dey)</b> 15. PAC a identify by b oviruses, ative virus stigate po flavivirus flavivirus therapeut liki Fores ese experind ations and ATION	SE COUNT 38 Act number) arenaviruses lem world- uses from otential uses ichinde) screens ic inter- t and Banzi ments will d anti-
D.H. Cor Annua 13a. TYPE OF Annua 16. SUPPLEM 17. FIELD 06 06 06 19. ABSTRAC JIN: wide, an four mere antivira (Banzi, were str of cand est. T weanling form the viral d 20. OISTRIBU EJUNCLAS 22a. NAME C	COSATI COSATI COSATI ENTARY NOTAT COSATI GROUP 13 03 Continue on fections c nd are a t dically im al therapi West Nile udied. Mo idate anti he most pr g mouse mo e basis for rugs	M. Sarzotti, 13b. TIME CO FROM_3/ TON CODES SUB-GROUP aused by exot hreat to becomportant group es. Select A b), Bunyavirus del systems within a substant omising Component dels, to estant or designing component aused by anti- the substant of asstract ED SAME AS I	I.P. Singh, H. DVERED 1/36_TO_2/28/87 I. SUBJECT TERMS ( Immunonodul combination and dentify by block of ic viruses are me more widely s were chosen a lphaviruses (Se uses (Bunyamwera, vere established unds were exami- blish minimal to combination there were. Dorne users	Lucia, and 14. DATE OF REPO 1987, M Continue on reverse ators, antiv therapy number) an important desiminated. is model syst mliki Forest LaCrosse), in vitro an compounds of ned in vivo, herapeutic 1 apies using 21. ABSTRACT SEC Unclassi 22b. TELEPHONE (	S. Baron RT (Yes, Month, arch 30 If necessary and irals, arbo publich he Represent ems to inve , Sindbis); and an Aren d <u>in vivo</u> . potential using Seml evels. The immune modu CURITY CLASSIFIC fied Include Area Cod	Ooy) 13. PAC distancily by b oviruses, a ealth prob ative virus stigate po Flavivirus (Pi In vitro therapeut liki Fores ese experin lators and CATION	SE COUNT 38 Moct number) arenaviruses lem world- uses from otential uses ichinde) screens ic inter- t and Banzi ments will d anti-
D.H. Cor Annua 13a. TYPE OF Annua 16. SUPPLEM 17. FIELD 06 06 19. ABSTRAC 20. OF Tan wide, an four mer antivir: (Banzi, were str of cand est. T weanlin form the viral d 20. DISTRIBU EUNCLAS 22a. NAME C Mrs.	COSATI COSATI ENTARY NOTAT ENTARY NOTAT COSATI GROUP 13 03 F (Continue on fections c nd are a t dically im al therapi West Nile udied. Mo idate anti he most pr g mouse mo e basis for rugs TON/AVAILAS SUFIEO/UNLIMIT DF RESPONSIBLE Virginia	M. Sarzotti, 13b. TIME CO FROM 3/ TON CODES SUB-GROUP Aused by exot hreat to becomportant group es. Select A ), Bunyavirus del systems with viral substant omising Compo dels, to esta or designing co HUTY OF ABSTRACT ED SAME AS F INDIVIDUAL M. Miller	I.P. Singh, H. DVERED 1/36_TO_2/28/87 I.S. SUBJECT TERMS ( Immunonodul combination and denuity by block of ic viruses are me more widely s were chosen a lphaviruses (Se tes (Bunyamwera, vere established tes identified bunds were exami- blish minimal to combination there were. Donc USERS	Lucia, and 14. DATE OF REPO 1987, M Continue on reverse ators, antiv therapy number) an important desiminated. is model syst mliki Forest LaCrosse), in vitro an compounds of ned in vivo, herapeutic 1 apies using 21. ASSTRACT SEC Unclassi 22b. TELEPHONE ( 301-663-73	S. Baron AT (Yes, Month, arch 30 If necessary and irals, arbo publich he Represent ems to inve , Sindbis); and an Aren d <u>in vivo</u> . potential using Seml evels. The immune modu CURITY CLASSIFIC fied reduce Area Code 325	Dey) 13. PAC d identify by b oviruses, a ealth prob ative viru estigate po flaviviru flavivirus (P In vitro therapeut liki Fores ese experin alators and CATION	SYMBOL MI-S
D.H. Cor Annua 13a. TYPE OF Annua 16. SUPPLEM 17. FIELD 06 06 19. ABSTRAC 20. OF transition wide, an four med antivira (Banzi, were stu of cand est. Ti weanling form the viral d	COSATI COSATI COSATI ENTARY NOTAT ENTARY NOTAT COSATI GROUP 13 03 f (Continue on a fections c nd are a t dically im al therapi West Nile udied. Mo idate anti he most pr g mouse mo e basis fo rugs TON/AVAILAB SSIFIED/UNUMIT FRESPONSIBLE Virginia 473, 84 MAR	M. Sarzotti, 13b. TIME CO FROM_3/ TON CODES SUB-GROUP Aused by exother hreat to becomportant group es. Select A b), Bunyavirus del systems with viral substant omising Component dels, to estant or designing component dels, to estant of ABSTRACT ED SAME AS IN INDIVIDUAL M. Miller B3 AF	I.P. Singh, H. DVERED 1/36_TO_2/28/87 IS. SUBJECT TERMS ( Immunonodul combination and denuity by block of ic viruses are me more widely s were chosen a lphaviruses (Se ses (Bunyamwera, vere established unds were exami- blish minimal to combination ther All other editions are of the set of the set of the set and the set of the set of the set and the set of the set of the set and the set of the set of the set of the set of the set of the set of the set and the set of the	Lucia, and 14. DATE OF REPO 1987, M Continue on reverse ators, antiv therapy number) an important desiminated. Is model syst mliki Forest LaCrosse), in vitro an compounds of ned in vivo, herapeutic 1 capies using 21. ABSTRACT SEC Unclassi 22b. TELEPHONE (/ 301-663-73 Nul exhausted. biolete.	S. Baron RT (Yes, Month, arch 30 If necessary and irals, arbo publich he Represent ems to inve , Sindbis); and an Aren d <u>in vivo</u> . potential using Seml evels. The immune modu CURITY CLASSIFIC fied mclude Area Code 25 	Doy) 15. PAC d identify by b oviruses, a salth prob ative virus stigate po Flavivirus (P In virus therapeut liki Fores ese experin lators an 22c Office SGRD-R CLASSIFICATIO	SE COUNT 38 Mode number) arenaviruses lem world- uses from otential uses ichinde) screens ic inter- t and Banzi ments will d anti- SYMBOL MI-S N OF THIS PAGE

The best and a second

BITTER MANY MARKARY PROVIDED RECEIPTED RECEIPTED RECEIPTED RECEIPTED RECEIPTED RECEIPTED

es. Steered

#### SUMMARY

Model systems for the <u>in vitro</u> and <u>in vivo</u> study of Alphaviruses (Semliki Forest, Sindbis), Flaviviruses (Banzi, West Nile), Bunyaviruses (Bunyamwera, La Crosse) and Arenaviruses (Pichinde) were established. Candidate antiviral compounds were screened using three tissue culture assay systems: pretreatment assay (interferon type), brief exposure cocultivation assay (2 hr decanting assay), and continuous cocultivation assay. On the basis of <u>in vitro</u> results, the dose responses of candidate compounds were determined <u>in vivo</u> using weanline mouse model systems. Data from these ongoing experiments are used to design experiments testing the interactions of individual antiviral drugs and immune modulators when used in combination.

Accesic 1 For	
NTIS CRA&I DTIC TAB [ Churchwordd ] Jacobication	
By Destruction	UNALITY NSCOTED
Plac ordry Coue	25
Det Control	
A-1	

#### FOREWORD

82749.4442748.41448.46848483448344

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or service of these organizations.

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978).

 $\sim$ 

### TABLE OF CONTENTS

Summary 1
Foreword 2
Scientific Report
Rationale
Experimental Methods 6
Results
Discussion and Conclusions10
Distribution List

	TABLE OF CONTENTS
	Paga
	rage
Sum	mary 1
For	eword
Sci	entific Report
	Rationale
	Experimental Methods
	Results7
	Discussion and Conclusions10
Dis	tribution List
Tab	les
1.	Tissue Culture Systems for Virus Assays
2.	Effect of Interferon Treatment on Arbovirus Replication14
3.	Effect of Antiviral Compounds on Arbovirus Replication in
	Tissue Culture with Drug Removed After 2 hr Incubation15
4.	Effect of CVI Preparations on Arbovirus Replication in
	Tissue Culture with Drug Removed After 2 hr Incubation16
5.	Effect of Antiviral Compounds on Arbovirus Replication
	in Tissue Culture Using a Continuous Overlay System17
6.	Effect of CVI Preparations on Arbovirus Replication in
	Tissue Culture Using a Continuous Overlay System
7.	Summary of Antibody Production
8.	In vivo Protection Against Semliki Forest Virus with
	Ampligen (PolyI:C)20
	2
	٤

a de la construcción de la constru

9.	In vivo Protection Against Semliki Forest Virus with
	Murine IFNα/β
10.	In vivo Protection Against Semliki Forest Virus with
	CL-246,73822
11.	In vivo Protection Against Banzi Virus with Chloroquine
	Administered Prophylactically at Time -24 and 0 hr23
12.	Lack of <u>In vivo</u> Protection Against Banzi Virus with
	Murine IFNa/B24
13.	In vivo Protection Against Banzi Virus with Polyclonal
	Antisera
14.	Comparison Between Ampligen and PolyI:CLC for Protection
	<u>in vivo</u> Against Banzi Virus26
15.	In vivo Protection Against Banzi Virus with CL-246,73827
16.	Combination Therapy Against Banzi Virus with Immune
	Globulin and PolyI:CLC
17.	Lack of IFN Production by Cells Treated in vitro with
	CL-246,73829
18.	Comparison Between Ampligen and PolyI:CLC for IFN
	Induction <u>in vivo</u>

1265325

100000

1222242

**YSSEN** 

K4557 222223

### Figures

Effect of Pichinde Infection on Strain 13 Guinea Pigs32
Change in Clotting Times in Strain 13 Guinea Pigs After
Infection with Pichinde Virus
Kinetics of Serum Interferon Production in CL-246,738
Induced Mice

4. Dose Response of Interferon Production in the Serum

#### Introduction and Rationale

The research being pursued under this contract has the ultimate goal of designing and identifying effective therapeutic and prophylactic regimes for the treatment of medically and militarily important viral infections. Specifically, we are concerned with Alphaviruses, Flaviviruses, Bunyaviruses, and Arenaviruses. It was the primary goal of the initial contract year to establish test systems in vitro and in vivo to allow us to investigate antiviral agents against representatives of each of these groups. The test systems would then be used to screen a variety of candidate antiviral drugs for efficacy in vitro. Promising substances would then be evaluated in primary test systems in vivo. Results from in vitro and in vivo efficacy, toxicity, and dose response experiments can then be used to design experiments to test the relative effectiveness of combinations of antiviral drugs and immunomodulators in the treatment of viral infections.

#### Experimental Methods.

<u>Viruses</u>. Seed Alphaviruses [Semliki Forest (SF), Sindbis (SB)], Flaviviruses [Banzi (BZ), West Nile (WN)] and Bunyaviruses [Bunyamwera (BW), LaCrosse (LAC)] were received from Dr. Robert Shope of the Yale Arbovirus Unit. Viruses were passaged in newborn mice to prepare virus stocks. Briefly, viruses were inoculated intracranially into suckling mice 1-2 days postpartum. At the first sign of illness, generally 2-4 days after virus challenge, the mice were sacrificed and a 10% brain suspension in Eagles Minimum Essential Media was prepared. Some mice were frozen (-70°C) immediately after sacrifice, for use in antibody preparation. The 10% brain suspensions were aliquoted and frozen (-70°C) for future use.

Pichinde virus was received from Dr. David Gangemi, University of South Carolina. The virus (0.1 ml) was inoculated i.p. into 450-500 g Strain 13 guinea pigs. The animals were sacrificed on day 6 post infection, and 10% spleen suspensions prepared. This virus suspension was repassaged in Strain 13 guinea pigs to prepare the final stock virus (passage 14), which was aliquoted and frozen (-70°C).

<u>Viral Pathogenicity</u>. Dilutions of stock arboviruses were inoculated into outbred, weanling mice (Strain ICR) (15-22 g) intraperitoneally (i.p.) for LD<sub>75</sub> determinations. SF and BZ viruses produced lethal encephalitis at days 5-7 and 6-9, respectively, with 0.2 ml of a virus dilution of  $10^{-0.5}$  producing 1 LD<sub>75</sub> in each case. SB, WN, BW and LAC gave irregular results when injected i.p., but produced the expected pathogenesis when given intracranially. Suckling mice are currently being evaluated for susceptibility to these viruses after i.p. challenge.

Pichinde virus (PIC) dilutions were inoculated i.p. into groups of strain 13 guinea pigs weighing 450-500 g. All animals died between days 13-19 after virus challenge, except for one in the  $10^{-4}$  dilution group. Thus, the LD<sub>50</sub> of our stock PIC appears to be less than 0.1 ml of a  $10^{-4}$  dilution.

<u>Tissue Culture Systems</u>. Tissue culture systems for the test viruses are outlined in Table 1. In general, three different <u>in vitro</u> assay systems are used to evaluate the relative antiviral effects of the candidate compounds. The first, interferon-type assay involves preincubation (24 hr) of the host cell monolayer with the compound of interest. The drug is then removed from the culture, and the monolayers challenged with virus. Viral plaque formation is evaluated after a further 24-48 hr incubation. In the second assay system cells are co-incubated with the drug dilutions and challenge virus for two hours. The monolayers are then decanted, removing unbound virus and the test drug, followed by addition of a methyl cellulose solution in media. The methyl cellulose overlay is added to increase the viscosity of the media, thereby decreasing virus spread and allowing the formation of discreet, countable virus plaques. During the remainder of the 24-48 hr incubation, the drug is removed from the system. The third assay system is analogous to the second (decanting) system, in that cells are not pretreated with the antiviral compound. In this continuous overlay system, the drug is not decanted from the monolayer after a 2 hr incubation. Instead, a more concentrated methyl cellulose overlay is used to promote plaque development.

PERSONAL PROPERTY

Antibody Production. Immune globulins were prepared by hyperimmunization of ICR (outbred) mice. Virus stocks (10% brain suspensions) were inactivated by incubation with  $\beta$ -propriolactone (37°, 2 hr), and diluted with Freund's complete adjuvant (1:1). The mixture (0.5 ml) was injected i.p. into adult mice. Antigen boosts were given at days 7, 14, 21 and 28. Ascitic fluid from immunized mice was withdrawn ad libitum, and antigen boosts were given as needed to stimulate production of ascitic fluid.

Animal Models. Protection against arbovirus infections is evaluated in vivo using weanling mouse models. Outbred mice, strain ICR, at 18-22 g (4-5 weeks) are inoculated with the drug to be evaluated. Route and schedule of drug delivery are dependent on the specific compound being evaluated. Virus challenge (1-3  $LD_{75}$ ) is administered i.p. Primary evaluation is by presence of an amelioration of lethal encephalitis. Mice are generally maintained for 12-14 days after virus challenge before an experiment is terminated, but all groups are held for at least 3 days after the last recorded death. Pichinde virus is administered i.p. to 450-500 g strain 13 guinea pigs, as outlined above.

#### Results

Antiviral Assays. Four interferon (IFN) preparations were assayed for inhibition of arbovirus replication in vitro: natural murine IFN $\alpha/\beta$ , natural murine IFN $\gamma$ , human recombinant IFN $\alpha$   $\overline{A/D}$ , and natural human IFN $\gamma$  (Table 2). The observed level of the antiviral effect of these interferons is clearly influenced both by the degree of susceptibility of the target virus to the protective effects of interferon and by the (often limited) amount of cross species activity shown by the interferons. The latter is dependent both on the origin of the interferon and the cell culture system used in the assay.

Non-interferon antiviral compounds were screened using both the 2 hr decanting and the continuous overlay assays. Results for the 2 hr decanting assay are shown in Tables 3 and 4, while results for the continuous overlay system are given in Tables 5 and 6. Some compounds did not show any antiviral effects beyond their toxic levels on particular cell lines. These drugs are indicated with minimum inhibitory concentrations (MIC) of greater than the toxic concentration (Tables 3,5); or with virus plaque reduction titers of less than the toxic level (Tables 4,6). Antibody Production. Antibodies were produced for all six arboviruses to be used in this research. High titer antibody pools were produced for all except the two alphaviruses, both of which induce low levels of neutralizing antibody, as has also been observed elsewhere (Table 7). Pichinde virus stock was treated as described above. The inactivated virus was mixed with Freund's complete adjuvant (1:1); 1 ml was injected i.p. weekly, for two weeks, into Hartley guinea pigs (500 g). All animals died of progressive viral disease within 12-16 days of the initial inoculation. Further attempts at antibody production are being pursued.

<u>Viral Pathogenicity</u>. Virus stocks of BZ and SF viruses produce lethal encephalitis 6-9 days after injection i.p. into weanling ICR mice. Stock WN, LAC, and BW viruses (0.03 ml) produce lethal encephalitis within 3-5 days when injected intracranially into 3-4 week old (16-17 g) ICR mice. Experiments to determine correct dosages and age of target animals for i.p. challenge with these viruses are ongoing. Histologic evaluation of arbovirus infections are also ongoing.

Twelve strain 13 guinea pigs (450-500 g) received 0.1 ml stock virus (passage 14) i.p. Animals were weighed three times a week. On days 4, 7, 11 and 15, animals were sacrificed, the blood collected in citrated collection tubes for clotting studies, and the organs processed for light and electron microscopy. The animals all lost a marked amount of weight (Figure 1). Their bodies seemed to lose muscle mass as well as fat. One animal died on day 13, and the remainder were either dead (3) or moribund (2) on day 14 post infection. The clotting studies revealed marked prolongation of the prothrombin (PT) and partial thromboplastin (APPT) times by Day 7 post infection (Figure 2). These abnormalities continued until death. Further evaluation of individual clotting factors is currently underway. However, the abnormalities seemed extreme for the amount of pathology seen in the liver and other tissues.

Lymph nodes, spleen, lung, liver, kidney, pancreas, and adrenal tissue were examined after fixation in neutral buffered formalin and routine processing for light microscopy. On Day 4, in the liver, a few foci of single-cell hepatocyte necrosis, surrounded by fragmenting PMNs were noted. All other organs were unremarkable. On Day 7, in the liver, these foci were more numerous. Cells were noted in which the nuclei had lost all stainable chromatin. These hollow nuclei resemble cells infected with HSV. The spleen and lymph nodes had decreased numbers of mature lymphocytes. A few areas of eosinophilic necrosis, with "hollow nuclei" at the margins were noted in the lymph nodes.

On Day 11, the animals had interstitial pneumonia, with both PMNs and macrophage infiltration of the septae. The livers showed moderate fatty metamorphosis, in addition to foci of necrosis with PMN infiltration. The kidney tubular epithelium showed foci of single-cell necrosis, especially in the straight tubules. The spleen and lymph nodes showed further loss of mature lymphocytes, with areas of necrosis in the periarteriolar lymphoid sheaths, encircling the lymphoid follicules. The adrenals had scattered foci of necrosis in the cortex with PMNs encircling the debris. All areas of necrosis were bordered by cells with "hollow nuclei".

On Day 14, the animals had moderately severe interstitial pneumonia. The livers had severe fatty metamorphosis, and many patches of necrosis. Fibrin deposition was noted in the areas of necrosis. The lymph nodes and spleens had marked loss of mature lymphocytes, and large numbers of PMNs and nuclear debris in patches of necrosis. The pancreas of two animals showed necrosis of the islet cells. The adrenals had many areas of necrosis with PMN infiltration.

It was notable that there were no areas of mononuclear cell infiltration in these organs. This is distinctly unusual for viral infections. The PMNs appear to be there in response to tissue necrosis, but there is no cellular reaction to the viral antigen that must be present in large quantities. NK function seems suppressed.

Single Drug Dose Response Experiments In Vivo. Single drug protection experiments using the SF model system were run using 6 candidate antivirals: NH<sub>4</sub>Cl, chloroquine, murine IFNa/ $\beta$ , non-peptide CVI, Ampligen and CL-246,738. Partial protection was seen for NH<sub>4</sub>Cl and non-peptide CVI. Strong protection was seen for Ampligen (Table 8), murine IFNa/ $\beta$  (Table 9) and CL-246,738 (Table 10), although a complete end point (non-protective dose) was not obtained for CL-246,738. Similar experiments using the BZ model system were done using chloroquine, immune globulin, murine IFNa/ $\beta$ , Ampligen, poly I:CLC, and CL-246,738. Partial protection was seen with chloroquine (Table 11); no protection was seen for murine IFNa/ $\beta$  (Table 12); and strong protection was noted for antibody (Table 13); Ampligen (Table 14), poly I:CLC (Table 14), and CL-246,738 (Table 15). All of these results are being confirmed and, where complete dose response data have not yet been obtained, extended.

<u>Combination Chemotherapy In Vivo</u>. Based on our preliminary single drug titrations, we have begun combination experiments <u>in vivo</u>. Initial experiments are designed as a 4 x 4 grid, using three doses of each test compound, as well as single drug controls. In addition, a drug toxicity control is included in all initial combinations. The protocol is outlined in Table 16, which shows results of combining anti-Banzi immune globulin with poly I:CLC. This experiment gave some indication of greater than additive protection, but will need to be repeated with lower levels of the two antiviral agents in order to confirm this result.

Interferon Induction by CL-246,738. Orally administered CL-246,738 was effective in protecting weanling mice from lethal SF- and BZ-produced encephalitis (Tables 10,15). Since the drug was suspected of being a potent inducer of IFN, we investigated IFN levels in mice given CL-246,738. Following oral administration of CL-246,738, the serum IFN titer reached a peak 24 hrs after treatment and declined thereafter (Fig. 3). Challenge of the treated mice with a second dose of the drug, 24 hrs or 48 hrs after the first dose, did not boost the serum IFN response. High levels of IFN were also found in peritoneal lavage fluid of mice treated orally 24 hrs earlier, with CL-246,738 (Fig. 4). IFN was never detected in the serum or in the peritoneal fluid of mice which had been injected with the drug 6 hrs earlier.

We then investigated which cells were responsible for the production of IFN in vivo. Spleen or peritoneal exudate cells (PEC), obtained from mice injected 6 or 24 hrs earlier with the drug, were cultured in vitro for 24 hrs. Culture supernatants were then tested for IFN activity. As shown in Figure 5, low levels of IFN were detectable in the culture supernatants of spleen cells obtained from mice 6 hrs after treatment with CL-246,738. Titers from spleen cell supernatants were maximal when cells were harvested 6 hrs after treatment of the mice. In contrast, high levels of IFN were produced when PEC were harvested from mice 24 hrs after CL-246,738 treatment. As observed in the serum, no detectable IFN was produced by PEC 6 hrs after the drug administration (Fig. 5). Interestingly, the highest IFN response was obtained with PEC from mice treated with the lowest dose of CL-246,738 (0.1 mg/mouse).

CL-246,738 was also tested in tissue culture systems in order to design drugs combination experiments in vivo. We studied whether murine or human lymphocytes could be induced in vitro with CL-246,738 to produce IFN (Table 17). In contrast to the results reported for the induction in vivo with CL-246,738, when murine cells were treated in vitro with CL-246,738, inconsistent results were obtained. Some IFN was obtained from PEC in exp. 1: however, in exp. 2 PEC were unresponsive to a broad range of treatment doses. Neither was IFN detected in culture supernatants of CL-246,738 treated human lymphocytes. When supernatants were harvested 48 hrs versus 24 hrs after CL-246,738 induction, no difference in the results was observed. The highest dose of CL-246,738 that could be used in tissue culture, without being toxic, was 10  $\mu$ g/ml. Ampligen, used as a positive control (50  $\mu$ g/ml) always induced 81-243 units of IFN in these cell cultures. Thus, CL-246,738 cannot be used in tissue culture systems as an IFN inducer. The drug may need to be metabolized in vivo in order to become an IFN inducer. The usefulness of the drug in human systems cannot be established by this approach (Table 17).

#### Discussion and Conclusions

Most of the preliminary work needed to design meaningful trials of combination therapies against model arboviruses has been accomplished during the initial year of the project, and combination experiments in vivo have begun. Included in the preliminary work has been growing of stock viruses, preparation of immune globulins, establishment of tissue culture assay systems for each virus, and establishment of animal model systems.

Broad scale tissue culture screens of candidate antivirals have allowed us to make initial priority decisions for <u>in vivo</u> experiments. Based on the data presented in Tables 2-6,  $CH_3NH_2HC1$ , theophylline, phenytoin, Mo-CVI and amantidine have been placed on hold as candidates for <u>in vivo</u> studies, while the IFNs, chloroquine, ribavirin, CL-246,738 and the non-peptide CVIs remain high on our list of candidate compounds. Other candidate compounds include the various immune modulators, which could not be evaluated in these tissue culture screens, and immune globulins prepared by us.

A number of tentative conclusions can be drawn from the interferon titrations (Table 2). First, both mouse IFN $\alpha/\beta$  and human rIFN $\alpha$  A/D seem to show high activity against Semliki Forest, Banzi, West Nile, Bunyamwera and LaCrosse virus, with markedly lower activity against Sindbis virus. Second, the highly species specific action of mouse IFN $\gamma$  makes comparative evaluation difficult, but both SF and WN viruses seem quite sensitive to its action. Third, the crude human IFN $\gamma$  preparation seems to be less active against Bunyamwera than SF or LAC viruses. All of the results from IFN titrations will need to be confirmed. It will be particularly important to test different IFN/virus combinations on the same cell lines in order to more accurately identify the cause of the variation seen. Finally, comparison of the in vitro and in vivo results for murine IFN $\alpha/\beta$ against SF (Tables 2,9) and BZ (Tables 2,12) again illustrate how vital it is to confirm tissue culture results in animal models. Single drug dose response experiments have allowed us to determine initial priorities for combination therapy experiments. Initial focus in combinatorial studies will be poly I:CLC, murine IFNa/ß, neutralizing antibodies, and CL-246,738. Other compounds which will probably be added to the list, based on the results of ongoing dose response experiments, are ribavirin, IFN $\gamma$ , non-peptide CVI, MD(T)P, TNF and <u>C. parvum</u>. Results from the first combination experiment, using BZ antigen and poly I:CLC (Table 16), indicate that our protocol will be effective in determining interactions of drugs <u>in vivo</u>.

Two similar immunomodulating drugs, Ampligen and poly I:CLC, were compared to test their effectiveness as antiviral agents. As shown in Table 14, Ampligen, at a dose of 8 x  $10^{-1}$  mg/kg, fully protected weanling mice against a lethal challenge with Banzi virus when given intraperitoneally. Ampligen was also totally protective against Semliki Forest virus at doses as low as 8 x  $10^{-1}$ mg/kg (Table 8). By contrast, poly I:CLC gave full protection against Banzi virus at a dose as low as 4 x  $10^{-2}$  mg/kg (Table 14). Thus, poly I:CLC was 20-fold more effective than Ampligen.

We had shown Banzi to be very sensitive to the action of IFN in vitro (Table 2). Thus, we investigated whether the greater efficacy of poly I:CLC versus Ampligen against Banzi virus correlated with a greater ability to induce IFN in vivo. As shown in Table 18, the IFN titers obtained in the serum and in the peritoneal cavity of mice injected with poly I:CLC 6 hrs earlier was much greater, on a per dose basis, than the IFN titers of mice injected with Ampligen. The IFN titers peaked at 6 hrs and declined 24 hrs after drug administration (data not shown). In summary, poly I:CLC seems to be a more effective antiviral drug than Ampligen, and as such it will be employed in future experiments.

We also evaluated the protection produced by the immunomodulator, CL-246,738. This drug, given orally, protected mice against lethal challenge with SFV or Banzi virus (Tables 10,15). In these experiments, a single oral dose of CL-246,738 was given 24 hrs before injection with the virus: full protection against the two viruses was obtained with drug's doses ranging from 0.1 mg/mouse (5 mg/kg) to 3 mg/mouse (150 mg/kg). High doses of the compound were potent inducers of interferon in serum and peritoneal fluid (Fig. 4). In fact, the levels detected in the peritoneal fluid are an underestimate, since 2 ml of media was added to the peritoneal cavity as a lavage to collect the induced IFN. Thus, the amounts of IFN detected (26-358 units/ml) represents a 10- to 100-fold dilution of the concentrations actually present in the peritoneal cavity.

Interferon was produced by both spleen and peritoneal exudate cells harvested from mice pretreated with CL-246,738. Interestingly, the kinetics of this induction were not the same in both cell types (Fig. 5). However, no consistent IFN production was seen when cells from untreated mice were induced in vitro with CL-246,738 (Table 17). This may indicate that a metabolic product of the compound is the actual inducer of IFN. Unfortunately, this finding makes it impossible to easily determine whether CL-246,738 is an effective IFN inducer in man (Table 17). It is not, however, certain that the only, or even the major, protective effect of CL-246,738 in vivo comes from the induction of IFN. For example, this compound produced complete protection in the BZ model system when a single oral dose (0.1 mg) was given prior to virus challenge (Table 15). This dose of CL-246,738 produced a 24 hr serum IFN titer of 200 U/ml (Fig. 4), which decreased to undetectable levels by 48 hrs. However, when IFNa/ $\beta$  was used in the same system, no protection was seen even when high doses (10,000 units/mouse) were administered (Table 12). Thus, this IFN dose, given i.p., was either not sufficient to perceptibly raise baseline IFN levels <u>in vitro</u>, which would be inconsistent with the parallel experiment in the SF model system (Table 9), or the major <u>in vivo</u> protective effects of CL-246,738 are through other immunomodulatory pathways.

	Cel	ls	Methyl Cellulose	Incubation
Virus	Preferred	Alternate	Overlay	Time
Alphaviruses				
Semliki Forest	VERO	CER, L929	0.5%	28 hr.
Sindbis	CER	WISH	0.8%/0.5%	25 hr.
Flaviviruses				
Banzi	CER	VERO	0.8%	48 hr.
West Nile	L929	CER, WISH	0.5%	48 hr.
Bunyaviruses				
Bunyamwera	CER	VERO	0.5%	45 hr.
La Crosse	VERO	CER	0.5%	55 hr.
Arenavirus				
Pichinde	MA-104	-	0.5%	6 days

h

## TABLE 1. Tissue Culture Systems for Virus Assays

Crude Hu Y (1,000 U/ml) Protective Titer ო ა < 3 729 162 e 9 σ Hu raA/D (1,000 U/m1) Protective 243 19**,**683 1,458 729 2,187 2,187 4,374 4,374 2,187 Titer Interferon Mu Y (1,000 U/m1) Protective 31,458 ۍ م 1,458 c e e **~** ~ Titer v v Mu a/B (100,000 U/m1) < 3 >59**,**049 59,049 Protective 6,561 39,366 ب م 59,043 >59,049 Titer Semliki Forest (VERO) (L929) Bunyamwera (CER) (VERO) West Nile (L929) LaCrosse (CER) (VERO) Virus (cell) Sindbis (CER) Banzi (CER) Flavivirus Alphavirus Bunyavirus

Effect of Interferon Treatment on Arbovirus Replication TABLE 2.

a 1995 - Second Second

14

v

ო ~

-	Minimum Inhibitory Concentration <sup>1</sup>								
Compound	<u>SB<sup>2</sup></u>	SF <sup>3</sup>	BZ <sup>4</sup>	wn <sup>5</sup>	BW <sup>6</sup>	LAC <sup>7</sup>			
$NH_4C1$ $NH_4C_2H_3O_2$ $NH_4NO_3$ $CH_3NH_2HC1$ Chloroquine CL-246,738 Amantidine Rimantidine Rimantidine	0.195 0.260 0.195 >0.500 0.008 0.002 0.030 0.170 0.063	0.260 0.391 0.391 0.500 0.100 0.002 0.500 0.125 0.500	1.040 1.560 1.040 >0.500 0.010 0.004 >0.500 0.250 0.170	0.521 0.781 0.521 >0.500 0.005 0.002 0.125 0.042 0.040	0.521 0.781 0.521 >0.500 0.004 >0.006 >0.500 0.250 0.004	0.200 0.200 0.140 0.008 0.002 ≥0.250 0.083 0.010			
Theophylline Phenytoin	>0.500 >0.250	>0.050 >0.500	>0.500 >0.250	>0.500 >0.250	>0.500 >0.250	>0.500 >0.250			

#### TABLE 3. Effect of Antiviral Compounds on Arbovirus Replication in Tissue Culture With Drug Removed After 2 hr Incubation

<sup>1</sup>MIC for 50% plaque reduction, in mg/ml Sindbis virus on WISH cells Semliki Forest virus on VERO cells Banzi virus on CER cells West Nile virus on CER cells Bunyamwera virus on CER cells La Crosse virus on CER cells

			Antivi	ral Titer	1		
Preparation	<u>sb</u> <sup>2</sup>	<u>sf<sup>3</sup></u>	BZ <sup>4</sup>	<u>wn<sup>5</sup></u>	<u>bw</u> <sup>6</sup>	LAC <sup>7</sup>	
P-8407	24	64	16	32	32	32	
PX-861	24	64	<2	16	48	48	
PX-862	<2	48	<2	<2	<2	<2	
PX-863	48	64	<2	48	64	48	
MO-CVI	<2	<2	<2	<2	<2	<2	
Milk Extract	>256	48	8	32	>256	>256	

#### TABLE 4. Effect of CVI Preparations on Arbovirus Replication in Tissue Culture With Drug Removed After 2 hr Incubation

1 250% plaque reduction titer 3Sindbis virus on WISH cells 3Semliki Forest virus on VERO cells 5Banzi virus on CER cells 6West Nile virus on CER cells 7Bunyamwera virus on CER cells 1La Crosse virus on CER cells

	Minimum Inhibitory Concentration <sup>1</sup>						
Compound	sb <sup>2</sup>	sf <sup>3</sup>	BZ <sup>5</sup>	wn <sup>5</sup>	bw <sup>6</sup>	LAC <sup>7</sup>	
NH4C1	0.260	0.521	0.521	0.521	0,521	0.521	
NH4C2H302	0.390	0.781	0.781	0.521	1.040	0.521	
NH4N03	0,260	0.781	0.521	0.521	0.781	0.391	
CH3NH2HC1	<u>&gt;</u> 0,500	0.167	<u>&gt;</u> 0.500	>0.500	>0.500	0.500	
Chloroquine	0.010	0.010	0.021	0.010	0.042	0.063	
CL-246,738	>0.013	0.004	0.004	0.003	0,006	0.008	
Amantidine	0,250	>0.042	>0.500	0.250	>0.250	0.083	
Rimantidine	>0.125	>0.063	0.125	0.042	>0.125	0.167	
Ribavirin	N.D.	0.167	>0.125	N.D.	>0,125	0.042	
Theophylline	>0.500	>0.250	>0.500	>0.500	>0.500	>0.500	
Phenytoin	>0.050	>0.025	>0.050	>0.050	>0.050	>0.050	

#### Table 5. Effect of Antiviral Compounds on Arbovirus Replication in Tissue Culture Using a Continuous Overlay System

1. MIC for 50% plaque reduction, in mg/ml

2. Sindbis virus on WISH cells

3. Semliki Forest virus on VERO cells

4. Banzi virus on CER cell

ĸŶĴŀĸŸĹŧĸŶĴŨĸŸĴĬĸŶĴŧĸŶĴŧĸŶĴŧĸŶĴŧĸŸĴĬĸŸĴĬĸŸĴŧĸŶĴŧĸŶĹŧĸŶĬŧŶĬŧŶĬŧĸŶĬŧĸŶĴŧĸŶĴĬĸŶĬĿĬĸŶ

5. West Nile virus on CER cells

6. Bunyamwera virus on CER cells

7. LaCrosse virus on VERO cells

	Antiviral Titer <sup>1</sup>								
CVI Preparation	sb <sup>2</sup>	SF <sup>3</sup>	BZ <sup>4</sup>	wn <sup>5</sup>	Bw <sup>6</sup>	LAC <sup>7</sup>			
P-8407	32	48	24	<256	64	32			
PX-861	16	4	<8	24	48	32			
PX-862	16	48	<32	<256	48	128			
PX-863	32	24	<32	<128	64	96			
MoCVI	<2	6	<2	2	<2	6			
Milk Extract	>256	6	<4	32	>256	128			

#### Table 6. Effect of CVI Preparations on Arbovirus Replication in Tissue Culture Using a Continuous Overlay System

1. 50% plaque reduction titer

2. Sindbis virus on WISH cells

3. Semliki Forest virus on VERO cells

4. Banzi virus on CER cell

5. West Nile virus on CER cells

6. Bunyamwera virus on CER cells

7. LaCrosse virus on VERO cells

			CDR Pu	rified
	Ascit	le Fluid	Anti	sera <sup>1</sup>
Virus	Volume (ml)	Avg. Titer	Volume	Titer
Alphaviruses				
Semliki Forest <sup>2</sup>	116 116 52	48 16 128	135 105	16 <u>&lt;</u> 4
Sindbis <sup>3</sup>	197	32	N.D.	N.D.
Flaviviruses				
Banzi <sup>3</sup>	188 50	256 <u>&gt;</u> 2,048	115 77	3,840 5,120
West Nile <sup>4</sup>	89	<u>&gt;</u> 30,000	N.D.	N.D.
Bunyaviruses				
Bunyamwera <sup>3</sup>	86 177	<u>&gt;</u> 4,096 <u>&gt;</u> 4,096	150 130	3,840 900
La Crosse <sup>3</sup>	26	<u>&gt;</u> 8,192	N.D.	N.D.

#### Table 7. Summary of Antibody Production

 $\frac{1}{2}$ Clarified with Whatman CDR Cellulose, and filter sterilized.

ŀ b

Assayed on VERO cells. Assayed on CER cells. Assayed on L929 cells.

Drug Dose mg/kg B.W.	Virus Dilution	Virus Dose <u>LD</u> 75	# Mice	% Mortality	% Protection Relative to Control
8.0	10-6.0	3	5	0	100
0.8	10 <sup>-6.0</sup>	3	5	0	100
0.08	10-6.0	3	5	0	100
0.008	10-6.0	3	5	0	100
0.0008	10-6.0	3	4	25	75
None	10-6.0	3	4	100	N.A.

# Table 8. In VivoProtection Against Semliki Forest VirusWith Ampligen (PolyI:C)

The drug (0.2 ml) was injected i.p. at -6 hrs

لتدود ومرار

Drug Dose Units/Mouse	Virus Dilution	Virus Dose	# Mice	% Mortality	% Protection Relative to Control
10,000	10-6.0	3	5	40	60
10,000	10-6.5	1	5	0	100
300	10-6.0	3	5	80	20
300	10 <sup>-6.5</sup>	1	5	40	50
10	10-6.0	3	5	100	0
10	10-6.5	1	5	60	25
None	10-6.0	3	5	100	NA
None	10-6.5	1	5	80	NA

Table 9. In Vivo Protection Against Semliki Forest Virus With Murine IFN  $\alpha/\beta$ 

The drug (0.2 ml) was injected i.p. at -1 hr

K

Drug Dose (mg/Mouse)	Virus Dilution	Virus Dose <u>LD</u> 75	<u># Mice</u>	% Mortality	<pre>% Protection Relative to Control</pre>
3.0	10-6.0	3	5	0	100
1.0	10-6.0	3	5	0	100
0.3	10-6.0	3	5	0	100
0.1	10-6.0	3	5	0	100
None	10-6.0	3	5	100	N.A.

Table 10. In Vivo Protection Against Semliki Forest Virus With CL-246,738

The drug (0.1 ml) was administered orally at -24 hrs

Drug Con- centration	Virus Dilution	Virus Dose <sup>LD</sup> 75	# Mice	% Mortality	<pre>% Protection    Relative to         Control</pre>
15 mM	10-6.0	3	10	50	37
15 mM	10-6.5	1	10	30	62
15 mM	-	-	5	0	N.A.
10 mM	10-6.0	3	10	80	0
10 mM	10-6.5	1	10	50	0
10 mM	-	-	5	0	N.A.
-	10-6.0	3	10	80	N.A.
-	10-6.5	1	10	50	N.A.

#### Table 11. In Vivo Protection Against Banzi Virus with Chloroquine Administered Prophylactically at Time -24 and 0 hr

<sup>1</sup>0.2 ml of chloroquine solution at the indicated concentrations were administered i.p. at the stated times.

Drug Dose Units/Mouse	Virus Dilution	Virus Dose LD <sub>75</sub>	<u> # Mice</u>	<pre>% Mortality</pre>	% Protection Relative to Control
10,000	10-6.0	3	5	100	0
10,000	10-6.5	1	5	100	0
300	10-6.0	3	5	100	0
300	10-6.5	1	5	100	0
10	10-6.0	3	5	100	0
10	10-6.5	1	5	100	0
None	10-6.0	3	5	100	NA
None	10-6.5	1	5	100	NA

Table 12. Lack of In Vivo Protection Against Banzi Virus With Murine IFN  $\alpha/\beta$ 

The drug (0.2 ml) was injected i.p. at -1 hr

Time of Treatment (hr)	Virus Dilution	Virus Dose <sup>LD</sup> 75	# Mice	% Mortality	% Protection Relative to Control
-24	$10^{-6.0}_{10^{-6.5}}$	3	5 5	0 0	100 100
+2	$10^{-6.0}$ $10^{-6.5}$	3 1	5 5	0 0	100 100
+24	$10^{-6.0}_{10^{-6.5}}$	3 1	5 5	40 20	60 73
+48	$10^{-6.0}_{10^{-6.5}}$	3 1	5 5	100 40	0 46
+72	$10^{-6.0}_{10^{-6.5}}$	3 1	5 5	100 20	0 73
Control	$10^{-6.0}_{10^{-6.5}}$	3 1	5 5	100 80	N.A. N.A.

#### Table 13. In Vivo Protection Against Banzi Viruses

With Polyclonal Antisera<sup>1</sup>

<sup>1</sup>250 Neutralizing units of antibody were administered i.p. at the stated times relative to administration of virus challenge.

Table 14. Comparison Between Ampligen and PolyI:CLC for Protection In <u>Vivo</u> Against Banzi Virus

1. V. S.

	Amp11ger		PolyI:CLC		
Drug Dose (mg/kg) <sup>a</sup>	Z Mortality	% Protection	(mg/kg)	Z Mortality	% Protection
8	U	100	4	C	100
0.8	0	100	0.4	0	100
0.08	20	80	0.04	0	100
0.008	20	80	0.004	40	60
0,0008	100	0	ÛŊ		ł
None	100	NA	None	100	NA

والمرجع والمرجع

20.0.0.0

 $^{a}$ 0.5 ml of drug at the indicated doses was given i.p. at -6 hrs (5 mice/group);  $^{3}\mathrm{LD}_{75}$  of Banzi virus was given i.p. at 0h.

26

Drug Dose (mg/Mouse)	Virus Dilution	Virus Dose <u>LD</u> 75	# Mice	<pre>% Mortality</pre>	<pre>% Protection Relative to Control</pre>
3.0	10-6.0	3	5	0	100
1.0	10-6.0	3	5	0	100
0.3	10-6.0	3	5	0	100
0.1	10-6.0	3	5	0	100
None	10-6.0	3	5	100	N.A.

1.1.1.1.1.1.1.1.1.

221 2222 B32322 LCC

Table 15. In Vivo Protection Against Banzi Virus With CL-246,738

The drug (0.1 ml) was administered orally at -24 hrs

U.

]	Drug Dose			
Antibody (Units)	PolyI:CLC (mg/kg Body Weight)	Nominal Virus Dose <u>LD</u> 75	% Mortality	% Protection Relative to <u>Control</u>
150	$4 \times 10^{-3}$	3	0	100
150	$2 \times 10^{-3}$	3	0	100
150	$4 \times 10^{-4}$	3	0	100
150	0	3	0	100
60	$4 \times 10^{-3}$	3	0	100
60	$2 \times 10^{-3}$	3	0	100
60	$4 \times 10^{-4}$	3	0	100
60		3	20	75
25	$4 \times 10^{-3}$	3	0	100
25	$2 \times 10^{-3}$	3	20	75
25	$4 \times 10^{-4}$	3	0	100
25		3	60	25
0	$4 \times 10^{-3}$	3	0	100
0	$2 \times 10^{-3}$	3	20	75
0	$4 \times 10^{-4}$	3	40	50
0	0	3	80	NA

#### Table 16. Combination Therapy Against Banzi Virus With Immune Globulin and PolyI:CLC

፟፟ዹ<sup>ጚ</sup>ቘቔኇዄቔኇዀዸኇዀጜፙዀጜቜዀ፟፟ዀዀዀ

Antibody was administered i.p. at -24 hrs, PolyI:CLC administered i.p. at -6 hrs, relative to virus inoculation.  $10^{-6}$  dilution of stock virus administered i.p. (5 mice/group) to all mice except for drug (toxicity) controls.

			IFN Tite	er
Exp.	Dose of Drug (µg/ml)	Murine Cell Spleen PEC	ls <sup>a</sup> <u>PBL</u>	Human Cells <sup>a</sup> Spleen PBL
1	5	<3 81	ND	<3 <3
	2.5	<3 54	ND	9 <3
	-	<3 27	ND	9 <3
2	10	<3 <3	<3	< 3 ND
	5	<3 9	<3	<3 <3
	2.5	<3 <3	<3	<3 <3
	1.2	<3 <3	<3	< 3 ND
	0.6	<3 3	<3	3 ND
	0.3	<3 9	<3	3 ND
	0.1	<3 18	<3	3 ND
	0.08	<3 <3	<3	3 ND
	-	<3 <3	<3	3 <3
	-	<3 <3		ر> د د

# Table 17.Lack of IFN Production by Cells TreatedInVitroVitrowith CL-246,738

ľ

6

<sup>a</sup>Cells were plated at 4 x  $10^5$ /well of a 96-well plate and treated with CL-246,738 at the doses indicated for 24 hrs. Culture supernatants were then tested for IFN activity in a standard IFN assay.

PolyI:CLC for Drug Dose (mg/kg)	Serum	Table 18. Comp. IFN IFN pligen Induction <u>i.p.<sup>c</sup></u>	arison Between Ampli. Induction In Vivo PolyI:CLC Induction Drug Dose (mg/kg) <sup>a</sup>	gen and Drug Dose <u>Serum</u>	1.p. <sup>c</sup>
æ	3,013	68	4	>6561	CN
0.8	83	CIN	0.4	46260	1791
0.08	₹30	5	0.04	2283	СN
0.008	€30	CIN	0.004	140	ND
0.0008	< 3U	<b>4</b> 3	QN	ł	1
None	<30	€ <b>,</b>	None	<b>∢</b> 30	¢3

\_average IFN titer (U/ml) of serum samples taken at 0h from 3 mice/group c\_average IFN titer of peritoneal lavages done at 0h to 3 mice/group (2 ml/mouse) ND - not determined



**Days after Infection** 

# Figure 1. Effect of Pichinde Infection on

# Strain 13 Guinea Pigs

Figure 1: Effect of Pichinde Infection on Strain 13 Guinea Pigs. Average weight loss of Strain 13 guinea pigs challenged with passage 14 Pichinde virus, compared to uninfected controls. Weights are expressed as a percent of the average starting weight.



Figure 2: Change in Clotting Times in Strain 13 Guinea Pigs After Infection with Pichinde Virus.

Plasma from infected animals was collected at days 4, 7, and 11 after infection. Clotting times for partial thromboplastin (APPT, Panel A) and prothrombin (PT, Panel B) assays are shown. Day 0 values are averages for uninfected guinea pigs: APTT normal range = 21-28 secs; PT normal range = 30-40 secs.





Figure 3: Kinetics of Serum Interferon Production in CL-246,738-Induced Mice.

Weanling mice were treated orally with CL-246,738 at 0, +24, and +48 hrs. Treated mice were bled at 6, 24, 48, and 72 hrs, and titers of circulating interferon determined.



CL-246,738 (mg/kg)

### A. SERUM

**B.** Peritoneal Lavage

Figure 4: Dose Response of Interferon Production in the Serum and Peritoneal Cavity of CL-246,738 Treated Mice.

Mice were treated orally with the indicated doses of CL-246,738.

Twenty-four hrs later blood was drawn from half the mice. The remaining mice were sacrificed. 2 ml of EMEM was injected into the peritoneal cavities as a lavage. The media was immediately withdrawn, and interferon titers were determined.



Time After Treatment (hr)

Time after Treatment (hr)

# A. Peritoneal Exudate Cells

# **B. SPLEEN CELLS**

Figure 5: Induction of Interferon in Peritoneal Exudate Cells and Spleen Cells from CL-246,738 Treated Mice.

Peritoneal exudate cells (Panel A) or spleen cells (Panel B) were prepared from mice pretreated with CL-246,738. Cells were cultured in vitro for 24 hrs, after which the supernatants were tested for IFN activity.

#### DISTRIBUTION LIST

- 5 copies Commander US Army Medical Research Institute of Infectious Diseases ATTN: SGRD-UIZ-M Fort Detrick, Frederick, MD 21701-5011
- 1 Copy Commander US Army Medical Research and Development Command ATTN: SGRD-RMI-S Fort Detrick, Frederick, Maryland 21701-5012

- 12 copies Defense Technical Information Center (DTIC) ATTN: DTIC-DDAC Cameron Station Alexandria, VA 22304-6145
- l copy Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799

l copy Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234-6100

